966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy
2021; Elsevier BV; Volume: 32; Linguagem: Inglês
10.1016/j.annonc.2021.08.1351
ISSN1569-8041
AutoresAlessio Cortellini, Domenico Mallardo, Sinéad Cleary, Melissa Bersanelli, Daniele Santini, Marco Tucci, Alessandro Russo, Francesca Rastelli, Marco Filetti, Alain Gelibter, Riccardo Marconcini, Rita Chiari, Francesco Grossi, Michele De Tursi, Paola Queirolo, Federica Zoratto, Enrica T. Tanda, Giampiero Porzio, Paolo A. Ascierto, David J. Pinato,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoChronic hyperglycemia is known to induce immune dysfunctions and multiple studies has identified resistance/adherence to insulin therapy as barriers to achieving an optimal glycaemic control in patients with diabetes mellitus (DM) after front line metformin failure. How DM affects the efficacy of immune checkpoint inhibitors (ICI) is yet to be defined.
Referência(s)